Status: Not yet recruiting
A Study to Evaluate ATX-898 in Participants With Advanced Solid Tumors
Study ATX-898-101 is a phase 1/2 open-label study evaluating the safety, tolerability, pharmacokinetic, and preliminary efficacy of ATX-898 as monotherapy and in combination with anti-neoplastic agents in selected solid tumors. This study consists of 2 parts. Part 1 evaluates ATX-898 as monotherapy and Part 2 evaluates ATX-898 in combination with anti-neoplastic agents of interest. Both parts will consists of a dose escalation portion and a dose expansion portion.
Participants needed: 343
Trial details
Phase: Phase 1, Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Antares Therapeutics, IncUpdated: Aug 17, 2026
Eligibility criteria
Has histologically or cytologically confirmed advanced solid tumor malignancy th... [+13]
Has history (within ≤2 years before screening) of a solid tumor or hematological... [+5]